CinCor Pharma Inc., a Cincinnati-based startup focused on the pharmaceutical treatment of cardio-renal diseases, closed a $143 million Series B round led by General Atlantic. New investors including Perceptive Advisors, BVF Partners, venBio Partners, Omega Funds, Lilly Asia Ventures and Sixty Degree Capital also participated in the funding, alongside previous backers Sofinnova Investments, Sofinnova Partners and 5AM Ventures. Jason Pitts, vice president at General Atlantic, will join CinCor’s board.
Sciwind Biosciences Co., a China-based developer of treatments for metabolic disease, completed a $70 million Series C round led by IDG Capital, Loyal Valley Capital and LYFE Capital. The company also appointed Xinle Wu to the post of chief scientific officer and Martijn Fenaux as senior vice president, nonclinical development and translational science. Mr. Wu was most recently senior scientific director at Lilly China Innovation and Partnership. Mr. Fenaux was previously at Terns Pharmaceuticals, Novartis and Gilead Sciences.
AUM Biosciences, which is focused on developing novel targeted oncology therapies, raised $27 million in Series A funding led by Everlife and Sprim Ventures. The company has offices in Singapore, Wilmington, Del. and Australia.
Akadeum Life Sciences Inc., an Ann Arbor, Mich.-based startup whose biological separation platform has applications in cell therapy and diagnostics, raised an oversubscribed $17.5 million Series B round. Arboretum Ventures led the investment, with Managing Partner Dan Kidle joining the board. Beringea, Agilent Technologies, BlueStone Venture Partners, Berkeley Catalyst Fund, Michigan Capital Network, Michigan Rise and others also contributed to the round.
AceCann, a Lisbon-based medical cannabis startup, was seeded with a $15 million investment. Casa Verde led the round, which included additional support from Lince Capital.
Better Health, a San Francisco-based medical supply and services provider to people with chronic conditions, picked up $10 million in Series A funding. Lead investors Caffeinated Capital and General Catalyst were joined by 8VC, Anorak Ventures and others.
ScienceIO, a healthcare data platform, emerged from stealth with $8 million in seed funding from investors including Section 32, Sea Lane Ventures, Quiet Capital, Dorm Room Fund, Toba Capital and Swell Partners. Additionally, ScienceIO hired Chuck Smolky as its first chief commercial officer. He was previously at Optum, Aetna and Health Fidelity.
Seraphina Therapeutics, a San Diego-based startup dedicated to advancing health through the discovery of essential fatty acids and micronutrient therapeutics, added $5 million in Series A funding from investors including Domain Associates.
KixCare Inc., a Canadian virtual pediatric-care platform, nabbed $2 million in seed funding. Esplanade Ventures led the investment, which included participation from Horizon Capital and others.
|